|Articles|February 1, 2003

Ms.Codit

Q: My doctors commonly use the following example in their dictation: "IDN back, no other suspicious lesions noted on complete general cutaneous skin exam." Would this documentation support a 99213, 99202, or 99242 level of care since six body areas are required to meet the documentation guidelines for the examination?

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe

Related Content

Are Private Dermatology Practices at Risk for Extinction? A New Survey Sheds Light

By Ashwin Krishnan,Shannon Heaning, Content Associate

June 30th 2026

The New Economics of Dermatology Claims: Understanding and Responding to Rising Denials

By Ashwin Krishnan,Matthew J. Elias, DO

June 23rd 2026

Contracts: The Most Important Document Most Clinicians Treat Like an Afterthought

ByJoseph Gatti, DMSc, MPAS, MBA, PA-C

May 28th 2026

Inside the Mind of NP and PA Candidates: What Employers Often Miss

ByJoseph Gatti, DMSc, MPAS, MBA, PA-C

April 3rd 2026

FAQtual Insights: The Contract Playbook Part 2

ByJoseph Gatti, DMSc, MPAS, MBA, PA-C,Maddi Hebebrand, MC, Associate Editor

March 23rd 2026

Latest CME

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Adaptive Learning

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Corey Cutler, MD, MPH, FRCP(C); Amin M. Alousi, MD; Mehdi Hamadani, MD; Anna Sureda, MD, PhD

Ms.Codit

Related Content

Are Private Dermatology Practices at Risk for Extinction? A New Survey Sheds Light

The New Economics of Dermatology Claims: Understanding and Responding to Rising Denials

Contracts: The Most Important Document Most Clinicians Treat Like an Afterthought

Inside the Mind of NP and PA Candidates: What Employers Often Miss

FAQtual Insights: The Contract Playbook Part 2

Latest CME

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Trending on Dermatology Times

AAD Pediatric AD Guidelines Back Roflumilast, Ruxolitinib, Tapinarof

Modern Psoriasis Treatment: From Topicals to IL-23 and IL-17 Biologics

Extended-Release Oral Minoxidil Shows Rapid Onset Of Hair Growth In Female Androgenetic Alopecia

ICYMI: EU Approves Upadacitinib for Severe Alopecia as US Review Remains Pending

Interim Trial Results and Preclinical Data Highlight Potential of ABS-201 in Androgenetic Alopecia